Yhp-743, a noval parp1/2 inhibitor for treatment of human triple-negative breast cancer with brca deficiency

• In: Posters H - Pharmacology
• At: PSWC, Melbourne (Australia) (2014)
• Type: Poster
• Poster code: PH-019
• By: JI, Ming (Beijing, China)
• Abstract:

  I.Background
  Triple-negative breast cancers (TNBC) occur more frequently in women, and the only available treatment for TNBC is chemotherapy. Targeting the nuclear enzyme Poly (ADP-ribose) Polymerase (PARP) represents a novel approach to treatment of TNBC. YHP-743, a potent small molecule inhibitor of PARP1/2, is being developed for treatment of..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login